AstraZeneca pill helps cut breast cancer progression risk

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts said on Sunday.

See the original article at: Honolulu Star-Advertiser